Added to YB: 2026-05-12
Pitch date: 2026-05-10
FHTX [neutral]
Foghorn Therapeutics Inc.
Author Info
No bio for this author
Company Info
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
Market Cap
$260.7M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.61
P/E
-3.81
EV/Sales
4.22
Sector
Biotechnology
Category
growth
Q1 Earnings Wire May 8, 2026 PM Drop - Foghorn Therapeutics Inc.
FHTX (earnings): Q1 collab rev $3.3M (down on Lilly timing), net loss $19.9M. $183.6M cash = runway into 1H 2028. FHD-909 (SMARCA2i) in Phase 1 w/ Lilly 50/50 co-dev; AACR data showed complete tumor regression + immune memory w/ anti-PD-1. CBPd-171 (ER+ breast ca) IND 2027, EP300 degraders (MM) beat inobrodib preclin, IND 2027.
Read full article (1 min)